We are live on ! Find out more
CORT icon

Corcept Therapeutics
CORT

189 hedge funds and large institutions have $1.43B invested in Corcept Therapeutics in 2017 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 65 increasing their positions, 46 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

262% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 13

139% more call options, than puts

Call options by funds: $11.7M | Put options by funds: $4.89M

73% more capital invested

Capital invested by funds: $824M → $1.43B (+$605M)

41% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 46

21% more funds holding

Funds holding: 156 → 189 (+33)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

3.67% more ownership

Funds ownership: 61.7% → 65.37% (+3.7%)

Holders
189
Holders Change
+33
Holders Change %
+21.15%
% of All Funds
4.71%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.15%
New
47
Increased
65
Reduced
46
Closed
13
Calls
$11.7M
Puts
$4.89M
Net Calls
+$6.79M
Net Calls Change
+$5.06M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$26.8M
2
Renaissance Technologies
Renaissance Technologies
New York
+$14.7M
3
Wells Fargo
Wells Fargo
California
+$9.23M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$8.89M
5
AAM
AMI Asset Management
California
+$7.87M

Top Sellers

1
Federated Hermes
Federated Hermes
Pennsylvania
-$33.2M
2
CCM
Consonance Capital Management
New York
-$28.7M
3
MWNA
Marshall Wace North America
New York
-$10.4M
4
ISL
Ingalls & Snyder LLC
New York
-$6.46M
5
Morgan Stanley
Morgan Stanley
New York
-$6.27M
Name Holding Trade Value Shares
Change 		Change in
Stake
RJA
76
Raymond James & Associates
Florida
$1.83M +$100K +6,720 +8%
HIM
77
Hillsdale Investment Management
Ontario, Canada
$1.74M – – –
RhumbLine Advisers
78
RhumbLine Advisers
Massachusetts
$1.73M +$25.1K +1,685 +2%
Barclays
79
Barclays
United Kingdom
$1.67M -$525K -35,207 -29%
IBT
80
International Biotechnology Trust
United Kingdom
$1.6M +$1.24M +83,000 New
CIA
81
Capital Impact Advisors
Massachusetts
$1.51M – – –
UBS Group
82
UBS Group
Switzerland
$1.47M +$151K +10,153 +15%
State of Wisconsin Investment Board
83
State of Wisconsin Investment Board
Wisconsin
$1.41M – – –
EI
84
EAM Investors
California
$1.4M -$61.1K -4,101 -5%
CCA
85
Catalyst Capital Advisors
New York
$1.39M +$136K +9,150 +15%
Los Angeles Capital Management
86
Los Angeles Capital Management
California
$1.35M +$812K +54,460 +349%
1CM
87
1492 Capital Management
Wisconsin
$1.35M +$1.04M +70,034 New
TAM
88
Tocqueville Asset Management
New York
$1.35M +$1.04M +70,000 New
MC
89
Menta Capital
California
$1.31M -$713K -47,818 -41%
CAM
90
ClariVest Asset Management
California
$1.31M +$1.01M +67,921 New
Susquehanna International Group
91
Susquehanna International Group
Pennsylvania
$1.31M -$939K -62,979 -48%
Bank of America
92
Bank of America
North Carolina
$1.3M +$182K +12,175 +22%
GAM
93
Gotham Asset Management
New York
$1.28M +$101K +6,793 +11%
MLICM
94
Metropolitan Life Insurance Company (MetLife)
New York
$1.22M – – –
PP
95
Paloma Partners
Connecticut
$1.21M -$71.3K -4,784 -7%
Allianz Asset Management
96
Allianz Asset Management
Germany
$1.19M +$638K +42,760 +226%
AIG
97
American International Group
New York
$1.18M +$68.1K +4,569 +8%
SIA
98
Sit Investment Associates
Minnesota
$1.17M -$32.8K -2,200 -4%
FDCDDQ
99
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.15M +$886K +59,397 New
SO
100
STRS Ohio
Ohio
$1.13M -$216K -14,500 -20%
2 3
4
5 6

CORT Hedge Fund Activity: Q3 2017 in Review

189 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2017, worth a combined $1.43B — up 73% from $824M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new CORT positions and 13 closed out — a net gain of 34 holders — while 65 added to existing stakes and 46 trimmed.

The largest buyer was Vanguard Group, adding an estimated $26.8M. The largest seller was Federated Hermes, cutting an estimated $33.2M.

  • 189 institutional investors held Corcept Therapeutics (CORT) as of Q3 2017, up from 156 in Q2 2017.
  • Funds reported $1.43B of Corcept Therapeutics stock for Q3 2017, up 73% quarter-over-quarter.
  • 47 funds opened new Corcept Therapeutics positions in Q3 2017 and 13 closed out, a net change of +34 holders.
  • The largest Corcept Therapeutics buyer in Q3 2017 was Vanguard Group, an estimated $26.8M added.
  • The largest Corcept Therapeutics seller in Q3 2017 was Federated Hermes, an estimated $33.2M sold.

Based on aggregated 13F filings for Q3 2017.